We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Sebia Showcases HbA1c Testing Solutions for Every Size Laboratory at AACC 2022

By LabMedica International staff writers
Posted on 26 Jul 2022
Print article
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)
Image: Sebia provides a solution for every size laboratory for HbA1c testing (Photo courtesy of Sebia)

Sebia (Lisses, France) is showcasing its wide portfolio of instruments and tests designed to address clinical needs and improve laboratory efficiency and safety at the 2022 AACC Clinical Lab Expo. From the lowest to the highest volumes, with standalone instruments to workcell configurations, Sebia will highlight various solutions for laboratories at the event.

At AACC 2022, Sebia is demonstrating the CAPILLARYS 3 TERA MC high throughput capillary electrophoresis system that allows the combination of one to three CAPILLARYS 3 TERA instruments to a Sebia loader, with a loading capacity of 528 samples in one row. This high volume workcell provides three hours autonomy on HbA1c, and hemoglobin testing, and more than two hours on proteins, processing up to 528 samples in one go. The system can be fed continuously with additional racks, and the reagent management system allows ad-hoc reagent addition at any time, without interruption. Sebia also highlighted its portfolio of tests from multiple myeloma to metabolic disorders, hemoglobinopathies and genetic diseases.

In addition, Sebia will showcase its fully automated, random access Alegria 2 ELISA platform with its comprehensive menu of antigen assays & panels utilizing a unique Monotest strip technology that allows serum, plasma, and fecal sample testing in the same run. Visitors to the company’s AACC 2022 booth can learn about Phoresis CORE, the unified software solution for labs utilizing Sebia instruments which offers traceable patient sampling from reagent to result, remote interpretation in real-time, from anywhere, and with comprehensive patient history for all of its assays. Visitors can also learn how labs can partner with the company for its Sebia Workflow Service to maximize automation, reduce errors, and improve workflow.
 

Related Links:
Sebia 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.